1. Home
  2. CUE vs PGP Comparison

CUE vs PGP Comparison

Compare CUE & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • PGP
  • Stock Information
  • Founded
  • CUE 2014
  • PGP 2003
  • Country
  • CUE United States
  • PGP United States
  • Employees
  • CUE N/A
  • PGP N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • PGP Finance Companies
  • Sector
  • CUE Health Care
  • PGP Finance
  • Exchange
  • CUE Nasdaq
  • PGP Nasdaq
  • Market Cap
  • CUE 91.9M
  • PGP 91.0M
  • IPO Year
  • CUE 2018
  • PGP N/A
  • Fundamental
  • Price
  • CUE $1.26
  • PGP $8.00
  • Analyst Decision
  • CUE Strong Buy
  • PGP
  • Analyst Count
  • CUE 5
  • PGP 0
  • Target Price
  • CUE $5.00
  • PGP N/A
  • AVG Volume (30 Days)
  • CUE 285.1K
  • PGP 39.8K
  • Earning Date
  • CUE 03-10-2025
  • PGP 01-01-0001
  • Dividend Yield
  • CUE N/A
  • PGP 10.84%
  • EPS Growth
  • CUE N/A
  • PGP N/A
  • EPS
  • CUE N/A
  • PGP N/A
  • Revenue
  • CUE $9,532,000.00
  • PGP N/A
  • Revenue This Year
  • CUE $73.11
  • PGP N/A
  • Revenue Next Year
  • CUE $11.02
  • PGP N/A
  • P/E Ratio
  • CUE N/A
  • PGP N/A
  • Revenue Growth
  • CUE 149.53
  • PGP N/A
  • 52 Week Low
  • CUE $0.45
  • PGP $5.83
  • 52 Week High
  • CUE $2.58
  • PGP $7.81
  • Technical
  • Relative Strength Index (RSI)
  • CUE 49.50
  • PGP 55.91
  • Support Level
  • CUE $1.27
  • PGP $7.90
  • Resistance Level
  • CUE $1.50
  • PGP $8.04
  • Average True Range (ATR)
  • CUE 0.12
  • PGP 0.10
  • MACD
  • CUE -0.01
  • PGP 0.02
  • Stochastic Oscillator
  • CUE 53.73
  • PGP 83.87

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest

PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.

Share on Social Networks: